Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ado-trastuzumab emtansine
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 30 for your search:
Start Over
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO27952, 2012-000660-22, NCT01641939
A Study of Kadcyla (Trastuzumab Emtansine) in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO28231, 2012-001628-37, NCT01702571
A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO28408, NCT02131064
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: YO28405, NCT02144012
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PembroMab, NCT02318901
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NSABP FB-10, NCT02236000
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJBMNTDM1, 2011-005437-39, NCT01565200
Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: EORTC-75111-10114, 2011-006342-32, NCT01597414
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO28230, 2012-001547-46, NCT01702558
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SAKK 22/10, 2012-002556-17, UNICANCER UC-0140/1207, NCT01835236
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-048, NCT01853748
HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HP-00056720, NCT01924351
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Bresat Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: IC 2013-03, NCT01975142
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1013-0164, NCT02073487
A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO29389, 2014-001237-83, NCT02289833
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14/0274, NCT02314481
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-409, NCT02326974
Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 65 and over
Sponsor: NCI, Other
Protocol IDs: RU011301I, NCI-2015-00468, P30CA015083, NCT02414646
Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 7900, NCI-2013-00552, P30CA015704, NCT01816035
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 042013-042, NCT01976169
A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ONT-380-004, NCT01983501
Start Over